Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN-001 with pembrolizumab in refractory biliary tract cancer
NCT05998447Phase 2Terminated
- Sponsor
- Genome & Company
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of LR20011 in biliary tract cancer (BTC), sponsored by Genome & Company. Started Sep 2023; status: terminated.
02
Drugs
LR20011
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05998447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998447.